Login to Your Account

Theraclone, Pfizer Ink Antibody Agreement Worth up to $632M

By Marie Powers

Thursday, January 20, 2011
Privately held Theraclone Sciences Inc., of Seattle, has grabbed a tiger by the tail, inking a multiyear research and development collaboration with Pfizer Inc. for the company's in situ therapeutic antibody rescue (I-STAR) technology. The deal makes Theraclone eligible to receive up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones, plus undisclosed royalties on future sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription